|
|||||
|
|
||||||
Journal of Clinical Oncology, Vol 24, No 24 (August 20), 2006: pp. 4041 © 2006 American Society of Clinical Oncology. DOI: 10.1200/JCO.2006.07.1902
Primary Cutaneous B-Cell LymphomaDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT To the Editor: We read with great interest the article by Zinzani et al1 regarding primary cutaneous B-cell lymphoma and associated clinical outcomes. The authors conclude that diffuse large B-cell lymphoma, leg type, has a significantly worse prognosis compared with follicle center and marginal-zone B-cell lymphomas of the skin with respect to overall survival. This study is important as it confirms the findings of several smaller studies such as that by Grange et al2 which previously identified disseminated disease and leg involvement as adverse prognostic features. The authors reference this important study in their text as "the previous largest series" of 145 patients, but the reference provided includes a variety of patients with T-cell lymphomas.3 We believe the authors intended to reference the series by Grange et al2 published in the Journal of Clinical Oncology in 2001, which specifically focused on patients with primary cutaneous B-cell lymphoma. In 2005, our group published an analysis of nearly 1,000 patients with primary cutaneous B-cell lymphoma based on data from the Surveillance, Epidemiology and End Results program registry.4 That series spanned 1973 to 2001 and demonstrated the prognostic relationships between Surveillance, Epidemiology and End Results histology (which included over 400 patients with diffuse large B-cell lymphoma), anatomic location, and relative survival as well as adjusted risk of death. These findings served as the basis for a primary cutaneous B-cell lymphoma prognostic index that incorporates the combination of histology and anatomic distribution with adjustment for age, sex, race, and treatment with radiotherapy. We feel that the findings of Zinzani et al1 are complementary and supportive to the primary cutaneous B-cell lymphoma prognostic index and that the clinical results from these large data sets, in addition to the other supportive literature, should serve as the basis on which future clinical decisions and prospective study should be based. Authors' Disclosures of Potential Conflicts of Interest The authors indicated no potential conflicts of interest. REFERENCES
1. Zinzani PL, Quaglino P, Pimpinelli N, et al: Prognostic factors in primary cutaneous B-cell lymphoma: The Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 24:1376-1382, 2006 2. Grange F, Bekkenk MW, Wechsler J, et al: Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study. J Clin Oncol 19:3602-3610, 2001 3. Grange F, Hedelin G, Joly P, et al: Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sezary Syndrome: The French Study Group on Cutaneous Lymphomas. Blood 93:3637-3642, 1999 4. Smith BD, Smith GL, Cooper DL, et al: The cutaneous B-cell lymphoma prognostic index: A novel prognostic index derived from a population based registry. J Clin Oncol 23:3390-3395, 2005
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||
|
Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|